Precise assignment of sialylation linkages at the glycopeptide level is of importance in 16 bottom-up glycoproteomics, and is also an indispensable step to understand the function of 17 glycoproteins in pathogen-host interactions and cancer progression. Even though some efforts 18 have been dedicated to the discrimination of α2,3/α2,6-sialylated isomers, unambiguous 19 identification of sialoglycopeptide isomers is still needed. Herein, an innovative strategy of 20 glycosyltransferase labeling assisted mass spectrometry (GLAMS) was developed. After specific 21 enzymatic labeling, oxonium ions from higher-energy C-trap dissociation (HCD) fragmentation 22 of α2,3-sailoglycopeptides generate unique reporters to distinctly differentiate those of α2,6-23 sailoglycopeptide isomers. Using this strategy, a total of 1,236 linkage-specific 24 sialoglycopeptides were successfully identified from 161 glycoproteins in human serum. 25 26
INTRODUCTION 27
Glycosylation is one of the most important post-translational modifications (PTMs) of 28 proteins 1 . It plays an indispensable role in a wide variety of biological and physiological 29 processes including protein folding 2 , cellular communication and signaling 3 , immune response 4 , 30 and pathogen-host interactions 5 . It was estimated that more than half of proteins in the human 31 proteome are glycosylated 6 . Glycosylation is generally classified into N-glycosylation and 32 mucin-type O-glycosylation. In N-glycosylation, the glycans are attached to asparagine residues 33 of proteins in the consensus motif Asn-X-Ser/Thr/Cys (X can be any amino acid except for 34 proline) 7 , whereas the glycan moieties are linked to serine or threonine residues of proteins in O-35 glycosylation 1 . N-acetylneuraminic acid (Neu5Ac) is most common form of diverse sialic acids 36 found on glycan chains in humans 8 . Neu5Ac is the frequently the terminal monosaccharide 37 residue that linked to galactose (Gal) via an α2,3 or an α2,6 linkage 9 . The two Neu5Ac linkage 38 isomers have important roles in pathogen binding. For example, avian influenza A viruses 39 preferentially bind to respiratory epithelial cells that contain α2,3-linked Neu5Ac moieties, while 40 human influenza viruses selectively bind to α2,6-linked Neu5Ac moieties 10 . In addition, altered 41 sialylation linkages is closely correlated with health status. In patients diagnosed with prostate 42 cancer, the structure of sialylated glycans released from the prostate-specific antigen (PSA) is 43 rich in α2,3 linkages, whereas the structure of sialylated glycans from healthy people's PSA is 44 predominantly via α2,6 linkages 11 . Without detailed information on sialylation linkages, it is 45 challenging to decipher the biological functions of sialoglycoproteins. 46 mass spectrometry (MS) [22] [23] [24] , have been used to distinguish α2,3 and α2,6-sialylated glycans, but 48 the location of corresponding glycosylation sites is not evident. The emerging technology of MS-49 based glycoproteomics 25-29 provides a high-throughput approach to analyze site-specific protein 50 glycosylation. Consequently, strategies for identifying sialylation linkages at the glycopeptide 51 level are required. Established chemical approaches 30, 31 modify not only sialic acids of the 52 glycan moiety but also acidic amino acid residues and the C-terminus of the peptide backbone, 53 which increases the complexity of spectra analysis, especially in relation to large scale 54 glycoproteomics data 32 . Pseudo MS 3 fragmentation 22 and ion mobility-mass spectrometry (IM-55 MS) 33 have also been applied to distinguish sialoglycopeptide isomers but this technology has 56 not been demonstrated (?effective) for large-scale glycopeptides analysis. Even though the 57 fragmentation of high energy C-trap dissociation (HCD) can achieve the high-throughput 58 assignment of α2,3/α2,6-sialoglycopeptide isomers, there are still many ambiguous 59 glycopeptides without sialylation linkage information 34 . 60
Enzymatic labeling has become a promising tool for probing proteins with specific 61 glycosylation because of its high specificity and mild reaction condition [35] [36] [37] [38] [39] [40] [41] . In our previous 62 research, a b1,4-N-acetylgalactosaminyltransferase from Campylobacter jejuni (CgtA) was 63 demonstrated to specifically recognize the Neu5Ac(α2,3)Gal epitope and transfer N-64 acetylgalactosamine (GalNAc) or N-azidoacetylgalactosamine (GalNAz) to Gal residue via β1,4 65 linkage 42 . Taking advantage of the specificity of CgtA, we herein report a new strategy for 66 identification of α2,3 and α2,6 sialoglycopeptide isomers by glycosyltransferase labeling assisted 67 mass spectrometry (GLAMS). As shown in Scheme 1, sialoglycopeptides (monosialylation for 68 example) without linkages information were treated with GalNAz labeling by CgtA. After HCD 69 fragmentation, if only the oxonium ions of HexNAc (N-acetylhexosamine, m/z 204) and Neu5Ac 70 (m/z 292) are observed in the spectrum, this identifies an α2,6 linkage; if one more oxonium ion 71 m/z 245 from GalNAz is included, then it represents an α2,3 linkage. We demonstrated the 72 capacity of GLAMS to effectively differentiate α2,3/α2,6 isomers using synthetic 73 sialoglycopeptides, and applied it to profile sialylated N-glycopeptides digested from serum 74 samples, in which we identified 1,236 linkage specific sialoglycopeptides with an improved 75 version of pGlyco 2.0 software 27 . 76
77

EXPERIMENTAL SECTION 78
Chemicals and materials 79
Amicon Ultra-0.5 Centrifugal Filter Unit with NMWL of 30 kD was obtained from 80 Sialylated oligosaccharide standards including 3'-sialyllactose (3SL) and 6'-sialyllactose 91 (6SL) were enzymatically synthesized using Pasteurella multocida α2,3-sialyltransferase 1 and 92 Photobacterium damselae α2,6-sialyltransferase as described before 43 . 93
Serum samples from four healthy people, ten patients with colon cancer and four patients 94 with liver cancer were provided by Georgia Cancer Center at Augusta University and stored at -95 80 °C until use. The protocol for serum sample preparation was approved by the Institutional 96
Review Board of Augusta University and was performed in accordance with the Helsinki 97
Declaration. All participants gave written informed consents. 98
Protein digestion 99
The protein digestion was performed using a filter aided sample preparation (FASP) 44 100 method with minor modification. Approximately 1 mg of total proteins from human serum was 101 subjected to FASP procedures. Samples were denatured in 20 μL of lysis buffer (4% SDS, 100 102 mM DTT, 20 mM Tris-HCl, pH 7.6) at 95 °C for 10 min. When the solution was cooled down to 103 room temperature, 1 mL of UA solution (8 M urea, 20 mM Tris-HCl, pH 8.5) was added. The 104 solution was gradually transferred into a 30 kD filter and centrifugated at 15,000 rpm at 20 °C 105 for 15 min. Then 100 μL of IAA solution (50 mM IAA in UA solution) was added to the filter 106 and incubated for 30 min in the darkness followed by centrifugation at 15,000 rpm for 10 min. 107
After that, 100 μL of UA solution and 200 μL of digestion buffer (100 μL of 50 mM NH4HCO3 108 each time) were added and centrifuged at 15,000 rpm for 10 min, respectively. Finally, 20 μg of 109 trypsin was added into the filter and incubated at 37 °C for 12 h. The tryptic peptides were eluted 110 using 100 μL of 50 mM NH4HCO3 for six times. The concentration of the collected peptides was 111 measured based on absorbance at 280 nm with Nanodrop. Five hundred µg of the peptides were taken and subsequently dried in Vacufuge at room temperature, then were lyophilized twice to 113 remove NH4HCO3. The dried samples were stored at −20 °C for further use. 114
Enrichment of glycopeptides 115
The enrichment of glycopeptides was performed using an iSPE HILIC cartridge by the 116 procedure of ZIC-HILIC 45 . Briefly, the HILIC cartridge was pre-washed with 300 µL of 0.1% 117 TFA and conditioning with 600 µL of 80% ACN containing 0.1% TFA. Peptide samples 118 dissolved in 400 µL of 80% ACN containing 0.1% TFA were loaded onto the cartridge. The 119 flow-through was reloaded onto the column for another two times. Then the column was washed 120 with 1.2 mL of 80% ACN containing 1% TFA. The glycopeptides were eluted using 750 µL of 121 0.1% TFA, 60 µL of H2O, 60 µL of 25 mM NH4HCO3 and 60 µL of 50% ACN. The fractions 122
were combined followed by lyophilization and stored at -20 °C. 123
Enzymatic labeling of glycopeptides 124
The b1,4-N-acetylgalactosaminyltransferase from C. jejuni (CgtA) and sugar nucleotide 125 UDP-N-azidoacetylgalactosamine (UDP-GalNAz) were prepared as described previously 42 . For 126 enzymatic labeling, the 40 µL reaction mixture containing the enriched glycopeptides, 50 mM 127
Tris-HCl buffer (pH 7.5), 5 mM MgCl2, 200 µM UDP-GalNAz and 10 µg CgtA was incubated 128 in a 37 °C water bath for 1 h. The reaction was quenched by adding 60 µL of ACN, 6 µL of 10% 129 TFA and 215 µL of ACN containing 1% TFA. Then the glycopeptides were purified with an in-130 house packed Amide HILIC microcolumn (6 mg of XAmide HILIC medium in a 200 µL tip) 131 which was preconditioned with 100 µL of 0.1% TFA and 200 µL of 85% ACN containing 0.1% 132 TFA. After loading the reaction mixture onto the tip column, the column was washed with 100 133 µL of 85% ACN, 0.1% TFA to remove salts and proteins. The glycopeptides were collected 134 using 200 µL of 0.1% TFA and lyophilized.
Nano LC-MS/MS analysis 136
Nano RP HPLC-MS experiments were performed on an LTQ-Orbitrap Elite mass 137 spectrometer (Thermo Fisher) equipped with EASY-spray source and nano-LC UltiMate 3000 138 high-performance liquid chromatography system (Thermo Fisher). The separation was 139 performed on an EASY-Spray PepMap C18 Column (75 μm × 50 cm, 2 μm, ThermoFisher, US) 140 with a linear gradient from 3% to 40% mobile phase B for 120 min at a flow rate of 300 nL/min 141 (mobile phase A: 1.95% ACN, 97.95% H2O, 0.1% FA; mobile phase B: 79.95% ACN, 19.95% 142 H2O, 0.1% FA). The mass spectrometer was operated in the data-dependent mode. A full-scan 143 survey MS experiment (m/z range from 375 to 2000; automatic gain control target, 1,000,000 144 ions; resolution at 400 m/z, 60,000; maximum ion accumulation time, 50 ms) was acquired by 145 the Orbitrap mass spectrometer, and ten most intense ions were fragmented by higher-energy C-146 trap dissociation (HCD) with an optimized stepped collision energy (SCE) of 30 ± 15% NCE. 147
Data analysis 148
The pGlyco 3.0 software (an improved version of pGlyco 2.0 27 ) was used to identify N-149 glycopeptides. In the glycan database, we defined an unnatural monosaccharide GalNAz (Gaz, 150 Z). We created all the possible "Gaz" containing human N-glycan sequences following the motif 151 H(A)(Z), where "H" represents Galactose, "A" represents Neu5Ac and "Z" represents GalNAz. 152
For the sialoglycopeptides identification, the raw data was first converted to an mgf file using as the digestion enzyme with maximum two missed cleavage sites allowed. The mass tolerance 160 for the precursor ions and the fragment ions was set to 10 ppm and 20 ppm, respectively. A total 161 false discovery rate (FDR) of 1% was applied to all data sets at the glycopeptide level. The 162 identified glycoproteins were annotated using Uniprot ID mapping 47 . 163
164
RESULTS AND DISCUSSION 165
The specificity of CgtA for Sialoglycopeptides 166
Our previous study showed that CgtA had a high specificity for (Neu5Ac-α2,3-Gal)-167 containing glycans 42 . To test its selectivity for sialoglycopeptides, we synthesized 23SP and 168 26SP (synthesis and data not published) as shown in Figure 1 . The activity of CgtA was 169 validated with sialolactose prior to the enzymatic reaction of sialoglycopeptides. After labeling 170
with GalNAz by CgtA, only α2,3-sialylated lactose showed a mass shift of 244 Da in the MS 171 spectrum and no substrate was obviously observed (Figure S1) , which indicated that CgtA had 172 good catalytic activity and high specificity as well. 173 ESI-MS was used to monitor the GalNAz labeling reaction for sialoglycopeptides. For 174 the α2,3-sialoglycopeptide 23SP, the monoisotopic peak at m/z 1032.0808 is from the triply 175 charged glycopeptide (Figure S2A) . After incubating with CgtA and UDP-GalNAz for 30 min, a 176 new dominant peak at m/z 1113.4422 with three positive charges was observed, which 177 correspond to the GalNAz labeled 23SP (Figure S2C) . However, we could still detect minor 178 substrate 23SP. The α2,6-sialoglycopeptide 26SP has the same exact mass (Figure S2B) as 23SP. After GalNAz labeling by CgtA, the strongest peak is located at the same exact position, and a 180 trace amount of product at m/z 1113.4422 was detected (Figure S2D) . This may result from the 181 very weak activity of CgtA for 2,6-sialylated glycans 42 . 182
The reaction time was further optimized to increase the conversion rate of GalNAz 183 labeling of 23SP. The reaction mixture at different time points was analyzed by LC-MS and the 184 reaction efficiency was calculated based on the peak area. For 23SP, in the first half an hour, the 185 reaction efficiency was dramatically increased. After that, the increase slowed down and the 186 reaction efficiency approached 100% at 60 min. Meanwhile, the conversion rate for the 26SP 187 remained unchanged (less than 1%) over time (Figure 2) . Finally, we chose 60 min as the 188 reaction time for the subsequent GalNAz labeling reactions. 189
190
Identifying Sialoglycopeptide Linkage Isomers by GalNAz Labeling and Tandem MS 191
Although discrimination of α2,3/α2,6-sialoglycopeptide isomers can be achieved by the 192 mass shift in primary MS as shown above, we cannot accurately determine the glycopeptide 193 sequence using only molecular weight information. Tandem MS is an effective way for 194 sequencing glycopeptides, and HCD-MS/MS is commonly used to analyze glycopeptides 195 because of the high accuracy and detectable diagnostic oxonium ions of monosaccharides 26-28, 48 . 196 It was also demonstrated that HCD with stepped collision energy (SCE) can simultaneously 197 determine the sequences of both glycans and peptides in a single run 27, 48 . To achieve a better 198 sequence coverage of glycopeptides on the Orbitrap we used, SCE was optimized with 199 glycopeptides enriched from human serum. The identification of N-glycopeptides was performed 200 using pGlyco 2.0 software 27 . A series of two-step SCEs and three-step SCEs were employed to 201 compare the number of identified glycopeptides. As shown in Figure S3 , with a three-step SCE 202
of "15-30-45", more glycopeptides can be identified from the same sample. 203
The optimized SCE-HCD-MS/MS was applied for sequencing 23SP and 26SP. After 204 GalNAz labeling, 23SP (Figure 3A) showed diagnostic oxonium ions of GlcNAc and Neu5Ac at 205 m/z 204.09 and 292.10, which are common features of sialoglycopeptides. Apart from these 206 oxonium ions, 23SP also had a strong unknown peak at m/z 245.09. Compared with the spectrum 207 of 23SP before GalNAz labeling (Figure S4) , we can obviously see that the peak with m/z 208 245.09 corresponds to the oxonium ion of GalNAz. Following the dissociation pathway of 209
GlcNAc 39, 49, 50 in Scheme S1A, a series of fragmentation ions of GalNAz in HCD were 210 illustrated in Scheme S1B. The peaks at m/z 245.09, m/z 227.08, m/z 209.07 and m/z 179.06, 211 which match the theoretical values very well, are diagnostic ions of GalNAz (Figure S5) . For 212 26SP (Figure 3B) , its spectrum showed that it shared similar fragmentation patterns with 213
GalNAz labeled 23SP. In the low m/z region, only diagnostic ions of GlcNAc and Neu5Ac were 214 observed, which clearly demonstrated that the GLAMS is an effective approach to distinguish 215 intact linkage specific sialoglycopeptides. 216 217
Linkage Specific Sialoglycopeptides in Human Serum 218
We then applied this method to analyze the N-linked α2,3/α2,6-sialoglycopeptides of 219 complex biological samples. Serum samples from healthy individuals (n = 4) and patients 220 diagnosed with liver cancer (n = 4) and colon cancer (n = 10) were used in this study. In the 221 beginning, we tried to perform the enzymatic labeling of the mixture of tryptic peptides and 222 glycopeptides. After drying from the FASP eluents, the mixture was not completely dissolved in 223 the Tris buffer (pH 7.5) for the enzymatic reaction, which may result from the existence of some 224 basic peptides. To solve the solubility issue, we adopted step-by-step glycopeptides enrichment 225 and enzymatic labeling as shown in the workflow Figure 4 . It turned out that the enriched 226 glycopeptides were dissolved in the basic buffer very well. This may be attributed to that 227 conjugated glycans increase the hydrophilicity of peptides and some sialoglycans decrease the 228 isoelectric points of peptides according to the previous findings 51, 52 . 229
All the serum samples were analyzed in three replicated LC-MS/MS runs for a large-230 scale study of N-linked sialoglycopeptides. Using the oxonium ions of GalNAz as a tag to mark 231 α2,3-sialylation, a total of 22,819 sialoglycopeptide spectra were identified with a 1% total FDR, 232 corresponding to 1,236 unique site-specific sialoglycans on 261 N-glycosylation sites from 161 233 unique glycoproteins (Table S1), among of which 53% was also identified previously using a 234 deglycosylation method 53 as shown in Figure S6 . For the distribution analysis of α2,3 or α2,6-235 sialylation (Figure 5A) , only 48 distinct site-specific sialoglycopeptides contained pure α2,3-236 sialylation linkage, 236 sialoglycopeptides contained hybrid sialylation, and all the rest were 237 uniquely 2,6-sialylated, which accounts for more than 77% of the identified sialoglycopeptides. 238 This is consistent with the previous result that α2,6-sialylation is dominant in sialylated N-239 glycans released from human serum samples 54 . Taking a closer look at the distribution of 240 sialylation levels, monosialylation is the major component in strictly α2,3 or α2,6-241 sialoglycopeptides, and 74% of the hybrid sialoglycopeptides are disialylated. 242
The percentage of the overall overlapped glycosites (Figure 5C ) and glycoproteins 243 ( Figure 5D ) in a specific type of serum is 72-80% and 65-78%, respectively. The percentage of 244 overlapping sialoglycopeptides (Figure 5B) in each kind of serum sample was significantly 245 lower than those of the glycosites and glycoproteins, reflecting the diversity of site-specific 246 glycosylation, especially for samples from colon cancer and liver cancer patients. A highly 247 glycosylated protein P01876 (IGHA1) was selected to demonstrate the diversity of site-specific 248 glycosylation in the three different sera. The previous study showed that IgA was α2,3 and α2,6-sialylated on N-glycans 55 . Here, we identified 35 unique sialoglycopeptides including α2,3 and 250 α2,6 linkages on one N-glycosylation site of IGHA1 (Table S2 ). In addition, we found some 251 unique sialoglycopeptides of IGHA1 expressed in a serum-specific manner. For example, only 252 unique α2,6-sialoglycopeptides were identified in serum from liver cancer patients 253 (representative spectrum in Figure S7 ) and normal people (representative spectrum in Figure  254 S8), whereas unique α2,6-sialoglycopeptides and one hybrid sialoglycopeptide were detected 255 from colon cancer patients' sera (representative spectra in Figure S9) . 256
CONCLUSIONS 257
Elucidating linkage-specific sialylation of glycoproteins is significant to understand 258 pathogen-host interactions and disease development. By integrating enzymatic labeling and MS-259 based glycoproteomics, we developed a high-throughput glycosyltransferase labeling assisted 260 mass spectrometry (GLAMS) to identify sialoglycopeptide linkage isomers. Facilitated by the 261 acceptor specificity of the glycosyltransferase CgtA toward the Neu5Ac(α2,3)Gal epitope, we 262 have demonstrated the distinct diagnostic oxonium ions as tags to effectively discriminate α2,3-263 and α2,6-sialoglycopeptide isomers using LC separation coupled with SCE-HCD-MS/MS 264 fragmentation. We also successfully applied this approach to a large-scale profiling of linkage-265 specific sialoglycopeptides in human serum samples. The strategy of GLAMS should be of great 266 benefit in investigating differential changes in response to disease states from a glycoproteomics 267 perspective, and has potential to contribute to biomarker discovery in many diseases. 
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